RBC Capital raised the firm’s price target on Edwards Lifesciences to $82 from $80 and keeps an Outperform rating on the shares as part of a broader research note previewing MedTech for 2024. The company experienced improvements in U.S. staffing throughout 2023, resulting in higher-than-initially-expected TAVR volumes, and 2024 should see Edwards Lifesciences with continued focus on TAVR execution and the Pascal ramp, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences downgraded to In Line from Outperform at Evercore ISI
- Edwards Lifesciences price target raised to $84 from $78 at Truist
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Edwards Lifesciences downgraded to Mixed from Positive view at OTR Global
- Edwards Lifesciences price target raised by $2 at Truist, here’s why
